Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,197
archived clinical trials in
Atrial Fibrillation

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840186
mi
from
San Antonio, TX
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840186
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840236
mi
from
Temple, TX
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840236
mi
from
Temple, TX
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840011
mi
from
Victoria, TX
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840011
mi
from
Victoria, TX
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840285
mi
from
Wichita Falls, TX
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840285
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840223
mi
from
Clinton, UT
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840223
mi
from
Clinton, UT
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840238
mi
from
Salt Lake City, UT
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840238
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840068
mi
from
Salem, VA
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840068
mi
from
Salem, VA
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840219
mi
from
Springfield, VA
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840219
mi
from
Springfield, VA
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840058
mi
from
Everett, WA
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840058
mi
from
Everett, WA
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840123
mi
from
Seattle, WA
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840123
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840019
mi
from
Tacoma, WA
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840019
mi
from
Tacoma, WA
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840256
mi
from
Beloit, WI
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840256
mi
from
Beloit, WI
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840293
mi
from
Madison, WI
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840293
mi
from
Madison, WI
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis Investigational Site Number 840282
mi
from
Wauwatosa, WI
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis Investigational Site Number 840282
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated:  2/19/2016
Sanofi-Aventis
mi
from
Buenos Aires,
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status: Enrolling
Updated: 2/19/2016
Sanofi-Aventis
mi
from
Buenos Aires,
Click here to add this to my saved trials
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Status: Enrolling
Updated:  2/23/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Status: Enrolling
Updated: 2/23/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Status: Enrolling
Updated:  2/23/2016
Northwestern University
mi
from
Chicago, IL
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Status: Enrolling
Updated: 2/23/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Status: Enrolling
Updated:  2/23/2016
University of Western Ontario
mi
from
London,
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Status: Enrolling
Updated: 2/23/2016
University of Western Ontario
mi
from
London,
Click here to add this to my saved trials
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated:  3/3/2016
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated: 3/3/2016
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated:  3/3/2016
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated: 3/3/2016
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated:  3/3/2016
1218.61.01029 Boehringer Ingelheim Investigational Site
mi
from
Brooklyn, NY
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated: 3/3/2016
1218.61.01029 Boehringer Ingelheim Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated:  3/3/2016
1200.131.00179 Boehringer Ingelheim Investigational Site
mi
from
Stony Brook, NY
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated: 3/3/2016
1200.131.00179 Boehringer Ingelheim Investigational Site
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated:  3/3/2016
Boehringer Ingelheim Investigational Site
mi
from
Austin, TX
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status: Enrolling
Updated: 3/3/2016
Boehringer Ingelheim Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps
Recording for Potential AF Drivers and Patient Specific Atrial Anatomy and Atrial Electrogram Maps Using an FDA Approved 64-Pole Basket Catheter (CONFIRM)
Status: Enrolling
Updated:  3/9/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps
Recording for Potential AF Drivers and Patient Specific Atrial Anatomy and Atrial Electrogram Maps Using an FDA Approved 64-Pole Basket Catheter (CONFIRM)
Status: Enrolling
Updated: 3/9/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation
Mangosteen Effects on Inflammatory Markers in Atrial Fibrillation Trial
Status: Enrolling
Updated:  3/14/2016
The Mayo Clinic
mi
from
Rochester, MN
Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation
Mangosteen Effects on Inflammatory Markers in Atrial Fibrillation Trial
Status: Enrolling
Updated: 3/14/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Status: Enrolling
Updated:  3/21/2016
Emory Saint Joseph's Hospital
mi
from
Atlanta, GA
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Status: Enrolling
Updated: 3/21/2016
Emory Saint Joseph's Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Status: Enrolling
Updated:  3/21/2016
Emory University Hospital Midtown
mi
from
Atlanta, GA
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals
Status: Enrolling
Updated: 3/21/2016
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pulmonary Vein Isolation Outcomes With Fish Oils
Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)
Status: Enrolling
Updated:  3/22/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Pulmonary Vein Isolation Outcomes With Fish Oils
Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)
Status: Enrolling
Updated: 3/22/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Pulmonary Vein Isolation Outcomes With Fish Oils
Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)
Status: Enrolling
Updated:  3/22/2016
University Medical Practice Associates 425 West 59th St. #9C
mi
from
New York, NY
Pulmonary Vein Isolation Outcomes With Fish Oils
Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)
Status: Enrolling
Updated: 3/22/2016
University Medical Practice Associates 425 West 59th St. #9C
mi
from
New York, NY
Click here to add this to my saved trials
Pulmonary Vein Isolation Outcomes With Fish Oils
Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)
Status: Enrolling
Updated:  3/22/2016
St.Luke's Hospital 1111 Amsterdam Ave. 3rd Floor Cardiology
mi
from
New York, NY
Pulmonary Vein Isolation Outcomes With Fish Oils
Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)
Status: Enrolling
Updated: 3/22/2016
St.Luke's Hospital 1111 Amsterdam Ave. 3rd Floor Cardiology
mi
from
New York, NY
Click here to add this to my saved trials
THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring
This Study Will Investigate the Association Between a Set of Single Nucleotide Polymorphisms (SNPs) and Atrial Fibrillation in Patients at High Risk of Developing Atrial Fibrillation. The SNPs Investigated Will Have Been Previously Shown to be Associated With the Atrial Fibrillation.
Status: Enrolling
Updated:  4/18/2016
Scripps Clinic
mi
from
La Jolla, CA
THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring
This Study Will Investigate the Association Between a Set of Single Nucleotide Polymorphisms (SNPs) and Atrial Fibrillation in Patients at High Risk of Developing Atrial Fibrillation. The SNPs Investigated Will Have Been Previously Shown to be Associated With the Atrial Fibrillation.
Status: Enrolling
Updated: 4/18/2016
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
University of Florida
mi
from
Gainesville, FL
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Georgia Health Sciences University
mi
from
Augusta, GA
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Georgia Health Sciences University
mi
from
Augusta, GA
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Tulane University Health Science Center
mi
from
New Orleans, LA
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Tulane University Health Science Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
University of Maryland School of Medicine
mi
from
Baltimore, MD
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Henry Ford Hospital
mi
from
Detroit, MI
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Montefiore Medical Center
mi
from
Bronx, NY
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Duke University
mi
from
Durham, NC
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Vanderbilt University
mi
from
Nashville, TN
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
University of Texas Medical Branch
mi
from
Galveston, TX
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Intermountain Medical Center
mi
from
Murray, UT
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
University of Utah Health Care
mi
from
Salt Lake City, UT
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
University of Utah Health Care
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Marshfield Clinical Research Foundation
mi
from
Marshfield, WI
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Marshfield Clinical Research Foundation
mi
from
Marshfield, WI
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
University of California at San Francisco
mi
from
San Francisco, CA
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated:  4/19/2016
Mount Sinai School of Medicine
mi
from
New York, NY
Clarification of Optimal Anticoagulation Through Genetics
A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients
Status: Enrolling
Updated: 4/19/2016
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Genotype-Guided Warfarin Therapy Trial
Randomized Controlled Trial of Genotype-Guided Dosing of Warfarin Therapy
Status: Enrolling
Updated:  5/5/2016
UNC Hospitals, UNC Anticoagulation Clinic at the Ambulatory Care Center (ACC), UNC Family Medicine Center Anti-coagulation Clinic
mi
from
Chapel Hill, NC
Genotype-Guided Warfarin Therapy Trial
Randomized Controlled Trial of Genotype-Guided Dosing of Warfarin Therapy
Status: Enrolling
Updated: 5/5/2016
UNC Hospitals, UNC Anticoagulation Clinic at the Ambulatory Care Center (ACC), UNC Family Medicine Center Anti-coagulation Clinic
mi
from
Chapel Hill, NC
Click here to add this to my saved trials